研究报告 Research Report 15 Aug 2024 中国生物制药 Sino Biopharmaceutical (1177 HK) 创新产品上市放量，24H1 收入及利润实现双位数增长 Innovative Product Driving Double-Digit Growth of Revenue in 2024H1 [Table_yemei 观点聚焦 1] Investment Focus | --- | --- | |-----------------------------------------------|---------------------| | [Table_Info] 维持优于大市 Maintain OUTPERFORM | | | 评级 | 优于大市 OUTPERFORM | | 现价 | HK$3.19 | | 目标价 | HK$5.65 | | HTI ESG | 1.3-2.0-3.7 | E-S-G: 0-5, (Please refer to the Appendix for ESG comments) | --- | --- | |------------- ...